{"analyses":[{"ciLowerLimit":"-0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.37","groupDescription":"Event Free Rate (%) at Year 1 ITT WT Population","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0647","paramType":"Difference in Event Free Rate","paramValue":"7.46","statisticalMethod":"Z-test"},{"ciLowerLimit":"-0.06","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"16.19","groupDescription":"Event Free Rate (%) at Year 2 ITT WT Population","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0516","paramType":"Difference in Event Free Rate","paramValue":"8.07","statisticalMethod":"Z-test"},{"ciLowerLimit":"-0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"14.91","groupDescription":"Event Free Rate (%) at Year 1 ITT Population","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0683","paramType":"Difference in Event Free Rate","paramValue":"7.19","statisticalMethod":"Z-test"},{"ciLowerLimit":"-0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.44","groupDescription":"Event Free Rate (%) at Year 2 ITT Population","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0625","paramType":"Difference in Event Free Rate","paramValue":"7.53","statisticalMethod":"Z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.53","upperLimit":"66.51","value":"62.02"},{"groupId":"OG001","lowerLimit":"48.04","upperLimit":"61.08","value":"54.56"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 1 ITT WT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.64","upperLimit":"45.22","value":"40.43"},{"groupId":"OG001","lowerLimit":"25.80","upperLimit":"38.92","value":"32.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"229"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 2 ITT WT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.29","upperLimit":"66.02","value":"61.65"},{"groupId":"OG001","lowerLimit":"48.09","upperLimit":"60.84","value":"54.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 1 ITT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.10","upperLimit":"44.37","value":"39.73"},{"groupId":"OG001","lowerLimit":"25.79","upperLimit":"38.63","value":"32.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Event Free Rate (%) at Year 2 ITT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"483"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"description":"The OS rate at the 1- and 2-year landmark time points after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"NUMBER","populationDescription":"The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Up to 41 months after first patient enrolled, years 1 and 2 reported","title":"Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}